Abivax Prices Oversubscribed $800M ADS Offering with 960,000-Unit Option
ABVX•Abivax upsized its American Depositary Shares offering to $800M (€702M) with underwriters granted option for 960,000 additional ADS, reflecting strong investor demand. It resumed trading of its €0.01 ordinary shares on Euronext Paris at 3:30 p.m. CEST after a halt for allocation confirmation and pricing.
1. Offering Priced and Sized
On July 1, 2026, Abivax priced its public offering of American Depositary Shares at $800M (€702M) after upsizing from initial targets. The offering was highly oversubscribed, demonstrating robust investor appetite for its clinical-stage pipeline.
2. Underwriters' Option Details
In conjunction with the offering, Abivax granted underwriters a 30-day option to purchase up to 960,000 additional ADS. Exercise of this overallotment could increase total proceeds and provide further capital flexibility.
3. Trading Resumption on Euronext Paris
Ordinary shares with €0.01 nominal value resumed trading on the regulated market of Euronext Paris at 3:30 p.m. CEST after a trading halt initiated at 9:00 a.m. CEST. The halt allowed for allocation confirmation and pricing announcement ahead of the offering.
4. Disclosure Correction
A subsequent correction clarified that the offering was priced at $800M (€702M), confirming both the oversubscription and upsizing details. This amendment ensured accurate disclosure of the offering’s terms and size.
